SecBot SecBot

RGNX drug pipeline

REGENXBIO Inc. · 4 rated drugs
$7.32
−4.2% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±5.8%
1-day, median of 7 events
IV rank
No data
No current options data
Rated drugs
4
1 bullish · 1 bearish · 2 mixed
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3
Time to marketIf positive Phase 3 data in Q4 2026, regulatory filing likely 2027 with potential FDA approval 2028 for wet AMD (subretinal). Diabetic retinopathy program (NAAVIGATE) is Phase IIb/III and further out.

surabgene lomparvovec Updated Jul 3

What to watch

Watch for topline Phase 3 data from ATMOSPHERE/ASCENT in Q4 2026, this is the single biggest binary event for RGNX. Interim ALTITUDE data at ASRS July 2026 provides a near-term sentiment check. The $100M AbbVie milestone extends cash runway into late 2027, reducing near-term dilution risk.

Bull case
  • Massive market opportunity: Wet AMD affects up to 2 million people in the US, Europe, and Japan, and current standard of care requires frequent injections every 1-4 months; a one-time gene therapy could disrupt the entire competitive landscape.
  • Big pharma validation: AbbVie collaboration (2021, $370M upfront + up to ~$1.4B in milestones) de-risks development and provides commercialization infrastructure. A $100M milestone was just triggered in June 2026 for dosing the first NAAVIGATE patient, extending cash runway.
  • Two delivery routes increase optionality: subretinal (for specialized centers) and suprachoroidal (potential in-office procedure), the latter could dramatically expand the addressable market if successful.
Bear case
  • Competitive gene therapy race is tight: Eli Lilly acquired Adverum's ixo-vec for $262M (Oct 2025) and 4D Molecular Therapeutics' 4D-150 is also in Phase 3 for wet AMD. Being first-to-market is not guaranteed and multiple entrants could split the market.
  • Subretinal delivery is a commercial bottleneck: It requires a vitrectomy procedure by a retinal specialist, limiting adoption vs. in-office suprachoroidal injection. If the suprachoroidal route takes longer to develop, the subretinal product may have slow uptake.
  • Clinical trial risk: Gene therapy has a history of inflammation and immune reactions. Any safety signal in the large Phase 3 program could delay or derail approval.
◆ mixed
Impact
PhaseBLA resubmission pending (accelerated approval) — prior BLA reached PDUFA Feb 8, 2026 and received a Complete Response L
Time to marketPotential US approval in roughly Q1–Q2 2027 if the BLA is resubmitted in Q3 2026 and granted accelerated approval (a post-approval confirmatory trial would still be required); approval is not assured.

NAVSUNLI clemidsogene lanparvovec Updated Aug 19

What to watch

Watch for the NAVSUNLI BLA resubmission before end of Q3 2026 and the FDA's acceptance/PDUFA date that follows (~6 months later), that PDUFA, not the resubmission itself, is the binary that will swing RGNX. Note the stock has already re-rated from ~$5.70 (May 2026) to ~$12 (Aug 2026) on the FDA alignment, so much of the good news may be priced in; the July 2026 ~$108M offering (~17-20% dilution) and Barclays' Aug 7 downgrade to Equal-Weight are offsetting negatives.

Bull case
  • FDA alignment (June 22, 2026) de-risked the path: resubmission for accelerated approval requires no new control arm, no new enrollment and no additional studies, per the company release and NeurologyLive.
  • First-in-class potential: if approved, NAVSUNLI would be the first gene therapy and first one-time treatment for MPS II, vs. Takeda's Avlayah which requires weekly IV infusions.
  • Regulatory support: Orphan Drug, Rare Pediatric Disease, Fast Track and RMAT designations from FDA and ATMP classification from EMA.
Bear case
  • The FDA already rejected the original BLA (CRL around the Feb 8, 2026 PDUFA, citing trial-design uncertainty), and approval on resubmission is not guaranteed; accelerated approval still requires post-approval confirmatory evidence.
  • Stock whipsaw risk is demonstrated: local catalyst data records a ~19% 5-day drop after the Feb 2026 CRL and a ~43% one-day drop on May 14, 2026 around a recorded CRL/clinical-hold catalyst.
  • Dilution: July 20, 2026 offering of ~10M shares at $9.00 plus pre-funded warrants raised ~$107.8M net, described as ~17-20% dilution of existing shares.
◆ mixed
Impact
PhasePhase 3 (pivotal topline complete; BLA submission planned)
Time to marketBLA submission expected Q3 2026; potential FDA accelerated approval guided to 2H 2027 (~1 year out, per company guidance)

RGX-202 Updated Aug 19

What to watch

Watch for the RGX-202 BLA submission announcement in Q3 2026 and FDA acceptance thereafter, that sets the review clock toward a possible 2H 2027 accelerated approval. The analyst mean price target of $22.80 (vs ~$12 now) assumes approval, so monitor FDA's willingness to accept microdystrophin expression as a surrogate (the agency's Feb 2026 CRL on REGENXBIO's RGX-121 cited surrogate-endpoint concerns) and watch for further dilution, as the July 2026 offering already added ~17-20% to share count.

Bull case
  • Pivotal Phase 3 AFFINITY DUCHENNE primary endpoint met with high statistical significance (p<0.0001); 93% of patients achieved >10% microdystrophin expression (Q1 2026 8-K, May 14, 2026)
  • Statistically significant correlation between microdystrophin expression and functional improvement (NSAA, n=9) supports a potential FDA accelerated-approval pathway in 2027 (Q1 2026 8-K)
  • BLA submission on track to begin Q3 2026, with potential accelerated approval guided to 2H 2027 (Q2 2026 8-K, Aug 6, 2026)
Bear case
  • July 2026 offering of ~10M shares at $9.00 plus pre-funded warrants (underwriters' option exercised in full) raised ~$107.8M but adds roughly 17-20% dilution to existing holders (July 20, 2026 8-K / newswire analysis)
  • Q2 2026 'profit' of $22.7M was milestone-driven (a $100M AbbVie payment), not product sales; core operations remain loss-making and Q1 2026 net loss was $90.1M (Q2 2026 8-K report)
  • FDA skepticism of surrogates is a live risk: REGENXBIO's RGX-121 (Hunter syndrome) received a Complete Response Letter in Feb 2026 citing, among other things, surrogate endpoint validity, the same logic class RGX-202's expression-based accelerated approval relies on (FDA catalyst records)
▼ bearish
Impact
PhasePhase I/II (on FDA clinical hold since January 2026)
Time to marketUnknown — far off at best. The program is on clinical hold in Phase I/II; even if the hold is lifted, a potential approval is likely several years away, and the hold could end the program.

RGX-111 Updated Aug 19

What to watch

For RGNX holders, RGX-111 is not the swing factor, watch for any FDA/company statement on whether the clinical hold is lifted (resolution would be a modest positive, continuation a lingering overhang), but the stock's real binaries are the RGX-202 BLA submission and pivotal wet-AMD topline expected in Q3-Q4 2026. For anyone trading the drug itself: there is no dated catalyst on the calendar, so treat RGX-111 as de-risked-to-negative until the hold status changes.

Bull case
  • The program is not formally discontinued: RGX-111 still appears among REGENXBIO's pipeline programs in the Q2 2026 earnings 8-K, leaving room for a hold-resolution outcome. (Source: Q2 2026 8-K filing analysis)
  • Street coverage on the parent company is constructive: analyst consensus as of Aug 2026 was 11 Buy + 6 Strong Buy + 2 Hold, 0 Sell, with a mean price target of $22.80 (median $19.50) versus a ~$10.91 observed price on Aug 12, roughly 62% implied upside per the analyst snapshot.
  • Several tracked institutions accumulated RGNX in 2026-Q2 13F filings, Susquehanna doubled (+190.8% shares), D.E. Shaw doubled (+149.2%), Citigroup doubled (+204.2%), Vanguard added (+33%). (Source: bull/bear case institutional-accumulation rows; delayed 13F data)
Bear case
  • FDA clinical hold placed January 2026 after a neoplasm (tumor) case in a Phase I/II participant, a serious safety signal that can end a gene-therapy program; no resolution is recorded in local data through August 2026. (Source: SEC-derived catalyst record, sentiment negative, confidence high)
  • The stock reacted negatively to the hold: -5.76% one-day move on the recorded catalyst date.
  • Regulatory headwinds across the platform: the sister MPS program RGX-121 received an FDA Complete Response Letter in February 2026 (concerns over study eligibility criteria, external-control comparability, surrogate endpoint validity), with the company appealing and planning resubmission, a reminder that these MPS gene therapies face a tough FDA bar. (Source: SEC-derived catalyst records + Feb 2026 8-K)

Past FDA events & how the stock moved

7 events
DateDrugEvent1 day5 days
May 14, 2026NAVSUNLIClinical hold−43.0%−32.8%
May 14, 2026NAVSUNLIComplete response letter−43.0%−32.8%
Feb 8, 2026NAVSUNLIPDUFA decision−0.2%−22.6%
Feb 7, 2026NAVSUNLIComplete response letter−0.2%−22.6%
Feb 1, 2026NAVSUNLIComplete response letter−3.4%−7.4%
Jan 1, 2026RGX-111Clinical hold−5.8%+4.2%
May 1, 2025NAVSUNLIAccelerated approval+8.2%−25.6%